leisure time -WSS

leisure time

author：explore 2025-09-04 22:14:46 - browse：96

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： ACIP vaccine advisory panel sees its vacancies filled

Wikipedia

WSS

Doctors on social media are being harassed and cyberbullied

STAT Boddities: What happens to the brain when we get scared?

Why Eli Lilly’s earnings didn’t quite live up to the hype

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Xenotransplantation trials will require adjusting expectations, experts say

Altering the blood type of lungs raises potential for universal organs for transplants

knowledge

leisure time

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Inside the rise of 'mukbang' eating videos

Medical leaders decry Supreme Court decision on affirmative action

Congress might make insulin pumps more accessible to the blind

BioMarin wins approval for gene therapy to treat hemophilia A

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Walensky prepares to leave CDC — and Congress — behind

Why don't Americans have at

Supreme Court strikes down use of affirmative action

Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Report cites 'urgent' need to recruit more diverse clinical trial participants

Why don't Americans have at

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Reanimated hearts work just as well for transplants, study finds

Report cites 'urgent' need to recruit more diverse clinical trial participants

hotspot

Wikipedia

Wikipedia

focus